20% OFF + Buy 2 Get 1 Free Use code BUNDLE20
Shop
Neuro Research Cellular Research Tissue Repair Research GH Research Metabolic Research
Membership Knowledge Base Partner Program Contact
Account Shop Now
Back to Metabolic Research
GLP-3 RT
GLP-3 RT
GLP-3 RT

Swipe for more images

Triple-Action Metabolic Agonist

GLP-3 RT

VANTA-GLP3-RT Metabolic Research

GLP-3 RT is a single-molecule triple agonist of the GLP-1, GIP, and glucagon receptors, studied for metabolic regulation, appetite signaling, and energy balance in research models.

Wed, Sep 2 - Sun, Sep 6
Free shipment protection
Overnight shipping available
We accept Pay VISA DISC AMEX
For laboratory and research use only. Not for human or veterinary consumption, and not for diagnostic or therapeutic use. These statements have not been evaluated by the FDA.

Product Details

GLP-3 RT

  • Triple receptor peptide that targets GLP-1, GIP, and glucagon pathways

    Studied for metabolic-regulation signaling in research models

  • Investigated for appetite-signaling and energy-balance pathways

    Long-acting profile in research settings

  • Typically referenced in once-weekly research protocols

Research Use Notes

  • Supplied as lyophilized powder

    Requires reconstitution before use

  • Research Water required for mixing (sold separately)

  • Allow powder to fully dissolve

Storage

  • Store lyophilized powder vial in freezer

Keep at 2 to 8°C

  • Protect from light and heat

    After mixing, keep refrigerated

  • Use within typical research handling window after reconstitution

Handling

Certificate of Analysis Third Party Tested ISO/IEC 17025 ACCREDITED
Latest ISO 17025 7x TESTING
99.85%
Purity
Passed full QC panel
VariantGLP-3 (RT) 10mg
Lot #RT0001
Labeled10mg
Actual10.27mg
Tested06/17/2026
Full QC Panel7x TESTING
Purity (HPLC) 99.85%
Net Peptide Content 10.27
Identity (HPLC) GLP-3 (RT) 10mg
HPLC Conformity 99.85%
Heavy Metals (ICP-MS) Not Detected
Sterility (PCR) No Growth
Endotoxin (USP <85>) NMT 0.05 EU/mL
ISO/IEC 17025 ACCREDITED
View COA
Sources & References Peer-reviewed research
New England Journal of Medicine

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

2023 · DOI: 10.1056/NEJMoa2301972 Jastreboff, M.D Ph.D
View Source
The Lancet

Effects of retatrutide on body composition in people with type 2 diabetes

2025 Tamer Coskun, MD
View Source
National Library of Medicine

Triple Agonism Based Therapies for Obesity

2025
View Source
The Lancet

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes

2023 Julio Rosenstock, MD
View Source
Sources & References Peer-reviewed research
New England Journal of Medicine

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

2023 · DOI: 10.1056/NEJMoa2301972 Jastreboff, M.D Ph.D
View Source
The Lancet

Effects of retatrutide on body composition in people with type 2 diabetes

2025 Tamer Coskun, MD
View Source
National Library of Medicine

Triple Agonism Based Therapies for Obesity

2025
View Source
The Lancet

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes

2023 Julio Rosenstock, MD
View Source
STARTING ATPremium Peptides
Shop Now